Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

T cell therapy for ALL

Dr Max Topp - University of Wurzburg, Wurzburg, Germany
T cell therapy for ALL ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017

The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017

Neuroblastoma and cell communication networks

Prof Walter Kolch - Systems Biology Ireland, UCD, Dublin, Ireland
Neuroblastoma and cell communication networks ( Prof Walter Kolch - Systems Biology Ireland, UCD, Dublin, Ireland )
11 Dec 2017

Shortening the time to manufacture CAR T-cells

Dr Partow Kebriaei - MD Anderson Center, Houston, USA
Shortening the time to manufacture CAR T-cells ( Dr Partow Kebriaei - MD Anderson Center, Houston, USA )
10 Dec 2017

Anti-BCMA CAR T cell therapy for multiple myeloma

Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Anti-BCMA CAR T cell therapy for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017

Data from the CLARITY trial of ibrutinib plus venetoclax

Prof Peter Hillmen - University of Leeds, Leeds, UK
Data from the CLARITY trial of ibrutinib plus venetoclax ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017

Mogamulizumab for cutaneous T- cell lymphoma

Prof Youn Kim - Stanford University, Stanford, CA
Mogamulizumab for cutaneous T- cell lymphoma ( Prof Youn Kim - Stanford University, Stanford, CA )
10 Dec 2017

Phase 1 study of Blu-285 in advanced systemic mastocytosis

Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
Phase 1 study of Blu-285 in advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017

Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial

Prof Peter Hillmen - University of Leeds, Leeds, UK
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017

Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma

Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study

Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017

ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma

Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017